ArticleTranslational cancer research2025
FBXO32 promotes gastric cancer progression by regulating NME1.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a prognostic prediction model for gastric cancer based on lipophagy-related genes.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer, a common cancer, has a high incidence rate, the 5-year survival rate of gastric cancer with distant metastasis is less than 10%, so finding new targets for gastric cancer is of clinical importance. As a member of the F-box protein family, F-box protein 32 (FBXO32) plays a role in various cancers, but its role in gastric cancer is currently unclear, this study mainly focused on the role and mechanism of FBXO32 in gastric cancer. Methods: The FBXO32 expression was found through The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The FBXO32 expression in cell lines was found through Western blot assay. Cell cloning assay and Cell Counting Kit-8 (CCK8) assay were used to investigate the effect of FBXO32 on gastric cancer cell proliferation. Wound-healing assay and transwell assay were used to research the effect of FBXO32 on gastric cancer cell metastasis. Cancer stem cell sphere-forming assay was used to find out the effect of FBXO32 on the stemness of gastric cancer cells. Nude mouse tumorigenesis assay was used to investigate the effect of FBXO32 on gastric cancer tumor growth. Results: It was found that FBXO32 expression is elevated in gastric cancer, which is associated with poor prognosis. In addition, FBXO32 expression is also elevated in gastric cancer cell lines. The knockdown of FBXO32 can inhibit the proliferation, migration, invasion and stemness of gastric cancer cells, inhibit the subcutaneous tumor formation of gastric cancer cells in nude mice, and increase the expression of non-metastatic cells 1 (NME1). Low expression of NME1 is associated with poor prognosis in gastric cancer. The knockdown of NME1 expression can offset part of the tumor suppressor activity of the knockdown of FBXO32. Conclusions: It is believed that FBXO32 promotes the progression of gastric cancer by regulating NME1. Most importantly, our findings could provide information for the mechanism of gastric cancer and the discovery of new targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.